Hansoh Pharma Initiates Phase II Clinical Trial of Oral GLP-1R Agonists HS-10501 and HS-10501-2 for Obesity Treatment

On May 6, Hansoh Pharma registered aA Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of Once-daily Oral HS-10501/HS-10501-2 in Overweight and Obese Subjects。

ComeSource:Official Website of Drug Clinical Trial Registration and Information Disclosure Platform

This is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study aimed at evaluating the efficacy of once-daily oral administration of HS-10501 and HS- in adult subjects who are overweight with at least one weight-related comorbidity and in those who are obese.Efficacy and Safety of 10501-2.

The study plans to enroll 540 subjects, who will be randomly assigned to receiveHS-10501（5mg、20mg）、HS-10501-2（5mg、10mg）, placebo treatment, once daily. The treatment duration for HS-10501 is 36 weeks,HS-10501-2 Treatment Duration is 26 Weeks.

The primary endpoint was the percentage change in body weight from baseline at Week 26.. Secondary endpoints includePercentage change in weight from baseline, absolute change in weight from baseline, proportion of participants with ≥ 5% weight loss from baseline, proportion of participants with ≥ 10% weight loss from baseline, change in BMI from baseline, change in waist circumference from baseline.Change in Systolic Blood Pressure from Baseline, Total Cholesterol（TC）etc.

Cover Source:Corporate Logo

Disclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment plans. If necessary, please consult and contact正规医疗机构.

Editor: Crescent Moon

PR Article Coordination: WeChat insightxb